Your browser doesn't support javascript.
loading
Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States.
Kalish, Heather; Klumpp-Thomas, Carleen; Hunsberger, Sally; Baus, Holly Ann; Fay, Michael P; Siripong, Nalyn; Wang, Jing; Hicks, Jennifer; Mehalko, Jennifer; Travers, Jameson; Drew, Matthew; Pauly, Kyle; Spathies, Jacquelyn; Ngo, Tran; Adusei, Kenneth M; Karkanitsa, Maria; Croker, Jennifer A; Li, Yan; Graubard, Barry I; Czajkowski, Lindsay; Belliveau, Olivia; Chairez, Cheryl; Snead, Kelly; Frank, Peter; Shunmugavel, Anandakumar; Han, Alison; Giurgea, Luca T; Rosas, Luz Angela; Bean, Rachel; Athota, Rani; Cervantes-Medina, Adriana; Gouzoulis, Monica; Heffelfinger, Brittany; Valenti, Shannon; Caldararo, Rocco; Kolberg, Michelle M; Kelly, Andrew; Simon, Reid; Shafiq, Saifullah; Wall, Vanessa; Reed, Susan; Ford, Eric W; Lokwani, Ravi; Denson, John-Paul; Messing, Simon; Michael, Sam G; Gillette, William; Kimberly, Robert P; Reis, Steven E; Hall, Matthew D.
Afiliação
  • Kalish H; Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894.
  • Klumpp-Thomas C; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
  • Hunsberger S; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Baus HA; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Fay MP; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Siripong N; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Wang J; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick MD 21702.
  • Hicks J; Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894.
  • Mehalko J; Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick MD 21702.
  • Travers J; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
  • Drew M; Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick MD 21702.
  • Pauly K; Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894.
  • Spathies J; Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894.
  • Ngo T; Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894.
  • Adusei KM; Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894.
  • Karkanitsa M; Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894.
  • Croker JA; Center for Clinical and Translational Science, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294.
  • Li Y; Joint Program in Survey Methodology, Department of Epidemiology and Biostatistics, University of Maryland College Park, College Park, MD 20742.
  • Graubard BI; Division of Cancer Epidemiology & Genetics, Biostatistics Branch, National Cancer Institute, National Institutes of Health, Bethesda MD 20894.
  • Czajkowski L; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Belliveau O; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Chairez C; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Snead K; Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick MD 21702.
  • Frank P; Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick MD 21702.
  • Shunmugavel A; Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894.
  • Han A; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Giurgea LT; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Rosas LA; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Bean R; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Athota R; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Cervantes-Medina A; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Gouzoulis M; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Heffelfinger B; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Valenti S; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Caldararo R; Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick MD 21702.
  • Kolberg MM; Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Kelly A; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
  • Simon R; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
  • Shafiq S; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
  • Wall V; Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick MD 21702.
  • Reed S; Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20894.
  • Ford EW; Center for Clinical and Translational Science, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294.
  • Lokwani R; Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20894.
  • Denson JP; Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick MD 21702.
  • Messing S; Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick MD 21702.
  • Michael SG; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
  • Gillette W; Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick MD 21702.
  • Kimberly RP; Center for Clinical and Translational Science, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294.
  • Reis SE; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Hall MD; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
medRxiv ; 2021 Jan 31.
Article em En | MEDLINE | ID: mdl-33532807
ABSTRACT
Asymptomatic SARS-CoV-2 infection and delayed implementation of diagnostics have led to poorly defined viral prevalence rates. To address this, we analyzed seropositivity in US adults who have not previously been diagnosed with COVID-19. Individuals with characteristics that reflect the US population (n = 11,382) and who had not previously been diagnosed with COVID-19 were selected by quota sampling from 241,424 volunteers (ClinicalTrials.gov NCT04334954). Enrolled participants provided medical, geographic, demographic, and socioeconomic information and 9,028 blood samples. The majority (88.7%) of samples were collected between May 10th and July 31st, 2020. Samples were analyzed via ELISA for anti-Spike and anti-RBD antibodies. Estimation of seroprevalence was performed by using a weighted analysis to reflect the US population. We detected an undiagnosed seropositivity rate of 4.6% (95% CI 2.6 - 6.5%). There was distinct regional variability, with heightened seropositivity in locations of early outbreaks. Subgroup analysis demonstrated that the highest estimated undiagnosed seropositivity within groups was detected in younger participants (ages 18-45, 5.9%), females (5.5%), Black/African American (14.2%), Hispanic (6.1%), and Urban residents (5.3%), and lower undiagnosed seropositivity in those with chronic diseases. During the first wave of infection over the spring/summer of 2020 an estimate of 4.6% of adults had a prior undiagnosed SARS-CoV-2 infection. These data indicate that there were 4.8 (95% CI 2.8-6.8) undiagnosed cases for every diagnosed case of COVID-19 during this same time period in the United States, and an estimated 16.8 million undiagnosed cases by mid-July 2020.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: MedRxiv Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: MedRxiv Ano de publicação: 2021 Tipo de documento: Article